Next generation anti-IL-1beta monoclonal antibody(Avalo Therapeutics)

N/A

Report date: 2024/06/14 17:39:22

Base Information

Drug NameNext generation anti-IL-1beta monoclonal antibody(Avalo Therapeutics)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAnti-Interleukin-1 beta
TargetsInterleukin-1 beta
Therapy Area/IndicationsN/A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAvalo Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesAvalo Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsN/A
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A